Following the announcement of hosting a significant event, Oragenics, Inc. (NYSE: OGEN) saw its stock conclude the previous trading session on an upward trajectory. In the last Friday session, OGEN stock exhibited a bullish trend, rising by 42.07% to close at $2.33.
Upcoming Webinar On Neurotrauma Medicine
Today at 12:00 PM ET, Oragenics (OGEN) will hold a webinar panel discussion on neurotrauma medicine. This talk will focus on the unmet medical requirements related to traumatic brain injury (TBI), sometimes referred to as concussions, and will examine the common causes of these injuries as well as their connections to other long-term neurological problems.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Oragenics will present their top medication candidate, ONP-002, a cutting-edge neurosteroid intended to treat mild traumatic brain injury, during the webinar. In addition, the business will go over the results of preclinical and Phase I trials as well as the specifics of a Phase II clinical research that will soon be carried out in acute and emergency rooms.
Esteemed speakers for the event include James P. Kelly, MA, MD, FAAN, FANA, Emeritus Professor of Neurology and PM&R at the University of Colorado School of Medicine, and Frank Peacock, IV, MD, FACEP, FACC, FESC, Vice Chair for Emergency Medicine Research at Baylor College of Medicine.
Innovative Drug Delivery And Strategic Partnerships
Oragenics is dedicated to enhancing the formulation of ONP-002 by increasing the percentage of the active compound in the final spray-dried intranasal powder. These improvements aim to optimize particle size, ensuring they are large enough to prevent deep lung inhalation while maximizing intranasal absorption and brain targeting.
This intranasal delivery method is crucial for bypassing the blood-brain barrier, facilitating rapid and efficient drug delivery to the brain within minutes. In preparation for the Phase II clinical trial, Oragenics has secured an adequate supply of intranasal devices and partnered with Avance Clinical Pty Ltd, a renowned Clinical Research Organization (CRO) based in Adelaide, Australia.
Preclinical studies have demonstrated that ONP-002 significantly improves molecular and behavioral outcomes following brain injury. Additionally, the intranasal delivery of ONP-002 as a nanoparticle has shown enhanced brain exposure and metabolism, underscoring the potential of this innovative treatment.
